Compare LOCL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | CTSO |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 45.7M |
| IPO Year | N/A | 2008 |
| Metric | LOCL | CTSO |
|---|---|---|
| Price | $1.11 | $0.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 16.9K | ★ 62.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | $36.93 | $7.29 |
| Revenue Next Year | $82.62 | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $1.39 | $0.60 |
| 52 Week High | $5.75 | $1.39 |
| Indicator | LOCL | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 20.81 | 55.37 |
| Support Level | N/A | $0.61 |
| Resistance Level | $2.75 | $0.74 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 18.67 | 64.38 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.